.jpg "A Director at Aerie Pharma (NASDAQ: AERI) is Buying Shares")
Today, a Director at Aerie Pharma (NASDAQ: AERI), Gerald Cagle, bought shares of AERI for $49.45K.
This recent transaction increases Gerald Cagle’s holding in the company by 6.64% to a total of $801.7K.
See today’s analyst top recommended stocks >>
Currently, Aerie Pharma has an average volume of 219.1K. The Company has a Price to Book ratio of 8.3513.
Based on 5 analyst ratings, the analyst consensus is Strong Buy with an average price target of $81.75, reflecting a -39.3% downside. 13 different firms, including Canaccord Genuity and Cantor Fitzgerald, currently also have a Buy rating on the stock. Starting in March 2018, AERI received 9 Buy ratings in a row.
The insider sentiment on Aerie Pharma has been positive according to 25 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aerie Pharmaceuticals, Inc. is a clinical stage pharmaceutical company. It focuses on the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The company’s product candidates are Rhopressa and Roclatan.
